Q1 2025 EPS Estimates for Dynavax Technologies Co. Increased by William Blair (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX) – Investment analysts at William Blair boosted their Q1 2025 EPS estimates for shares of Dynavax Technologies in a research report issued to clients and investors on Tuesday, August 6th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings of $0.04 per share for the quarter, up from their prior forecast of $0.03. The consensus estimate for Dynavax Technologies’ current full-year earnings is $0.12 per share. William Blair also issued estimates for Dynavax Technologies’ Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.10 EPS and Q4 2025 earnings at $0.03 EPS.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $73.80 million during the quarter, compared to analysts’ expectations of $76.92 million. Dynavax Technologies had a net margin of 3.91% and a return on equity of 1.52%. During the same period last year, the business earned $0.03 EPS.

Other analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research note on Wednesday. The Goldman Sachs Group lowered their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday. Finally, StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, Dynavax Technologies has a consensus rating of “Moderate Buy” and a consensus price target of $23.67.

Dynavax Technologies Stock Performance

DVAX stock traded up $0.40 during trading on Thursday, reaching $11.10. The company had a trading volume of 2,976,587 shares, compared to its average volume of 2,151,702. The firm has a 50-day simple moving average of $11.20 and a 200-day simple moving average of $11.84. The company has a market cap of $1.45 billion, a price-to-earnings ratio of 185.00 and a beta of 1.28. The company has a debt-to-equity ratio of 0.36, a quick ratio of 14.10 and a current ratio of 15.20. Dynavax Technologies has a twelve month low of $9.74 and a twelve month high of $15.15.

Insider Buying and Selling at Dynavax Technologies

In other Dynavax Technologies news, Director Francis Cano sold 3,615 shares of Dynavax Technologies stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.93, for a total transaction of $43,126.95. Following the completion of the sale, the director now directly owns 36,905 shares in the company, valued at approximately $440,276.65. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.98% of the company’s stock.

Hedge Funds Weigh In On Dynavax Technologies

Several large investors have recently made changes to their positions in DVAX. Kynam Capital Management LP lifted its stake in shares of Dynavax Technologies by 180.0% in the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock valued at $52,616,000 after purchasing an additional 2,725,397 shares during the period. Eventide Asset Management LLC lifted its stake in shares of Dynavax Technologies by 103.0% in the 4th quarter. Eventide Asset Management LLC now owns 2,893,435 shares of the biopharmaceutical company’s stock valued at $40,450,000 after purchasing an additional 1,468,435 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Dynavax Technologies by 21.8% in the 4th quarter. Goldman Sachs Group Inc. now owns 3,597,139 shares of the biopharmaceutical company’s stock valued at $50,288,000 after purchasing an additional 644,428 shares during the period. UBS Group AG lifted its stake in shares of Dynavax Technologies by 427.2% in the 4th quarter. UBS Group AG now owns 647,911 shares of the biopharmaceutical company’s stock valued at $9,058,000 after purchasing an additional 525,012 shares during the period. Finally, Mizuho Markets Americas LLC lifted its stake in shares of Dynavax Technologies by 37.9% in the 2nd quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock valued at $13,196,000 after purchasing an additional 323,050 shares during the period. 96.96% of the stock is currently owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.